Scilex Holding (SCLXW) Long-Term Investments (2021 - 2026)
Scilex Holding (SCLXW) recorded quarterly Long-Term Investments of $4.8 million in Q1 2026, down 96.97% quarter-over-quarter from $159.4 million in Q4 2025, and down 93.89% on a YoY basis from $79.1 million in Q1 2025.
Scilex Holding (SCLXW) Long-Term Investments (2021 - 2026) Analysis & Trends
Scilex Holding's Long-Term Investments history runs 5 years deep, the most recent figure standing at $4.8 million for Q1 2026.
- In Q1 2026, Long-Term Investments fell 93.89% year-over-year to $4.8 million; the TTM figure through Mar 2026 stood at $4.8 million (down 93.89% YoY), while the FY2025 annual figure was $159.4 million, changed N/A from the prior year.
- Long-Term Investments was $4.8 million for Q1 2026 at Scilex Holding, down from $159.4 million in the prior quarter.
- In the past five years, Long-Term Investments ranged from a high of $159.4 million in Q4 2025 to a low of $2.4 million in Q3 2024.
- Historically, Long-Term Investments has averaged $72.0 million across 4 years, with a median of $79.1 million in 2025.
- The sharpest annual moves came in 2022 and 2026: Long-Term Investments soared 90030473.08% in 2022, then tumbled 93.89% in 2026.
- A 4-year view of Long-Term Investments shows it stood at $101.3 million in 2022, then tumbled by 97.66% to $2.4 million in 2024, then surged by 6611.71% to $159.4 million in 2025, then tumbled by 96.97% to $4.8 million in 2026.
- The last three Long-Term Investments figures came in at $4.8 million (Q1 2026), $159.4 million (Q4 2025), and $16.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | 133.47 Mn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 3.12 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | - |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 268.00 Mn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 1.11 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 983.00 Mn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 1.63 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 366.00 Mn |
| 10 | Scilex Holding | - | - | 4.15 Mn | 4.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.83 Mn |
| Dec 31, 2025 | 159.40 Mn |
| Sep 30, 2025 | 16.35 Mn |
| Jun 30, 2025 | 2.47 Mn |
| Mar 31, 2025 | 79.10 Mn |
| Sep 30, 2024 | 2.38 Mn |
| Sep 30, 2022 | 101.29 Mn |
| Jun 30, 2022 | 141.59 Mn |
| Mar 31, 2022 | 140.45 Mn |
| Dec 31, 2021 | 139.41 Mn |
| Sep 30, 2021 | 139.41 Mn |
| Jun 30, 2021 | 139.41 Mn |
| Mar 31, 2021 | 156.00 |